Nectar Lifesciences, a leading integrated pharmaceutical organization, has been granted ‘Certificate of Suitability’ for its key sterile molecule Cefuroxime Sodium in European Union (EU). The company already has EU cGMP approval for Cefuroxime Sodium, which was granted in October, 2011.
Cefuroxime Sodium is marketed by Innovator GSK as ZINACEF TM in EU and US as injectable is a $500 million molecule globally, of which, European sales constitute approximately 35% ($175 million). This translates into a significant opportunity for the company as indisputably one of the largest global player in cephalosporins which includes Cefuroxime Sodium in terms of production capacity for APIs.
The company already has developed formulations for Cefuroxime injections (750 mg and 7.5 g) and has already filed ANDA for US and will very soon file MAA in EU in current financial year.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: